Emerging research on peptides for autoimmune conditions
I · THE PARADOX OF CONVENTIONAL IMMUNE SUPPRESSION The drugs that have defined autoimmune treatment for half a century work
I · THE PARADOX OF CONVENTIONAL IMMUNE SUPPRESSION The drugs that have defined autoimmune treatment for half a century work
Thymosin Alpha-1 has more clinical data than most FDA-approved drugs in the immunology space and is approved in 35 countries,
BPC-157 was discovered in the gut, and the gastrointestinal tract remains the most evidence-supported target for this peptide across the
BPC-157 is a well-studied peptide with a specific mechanism and a defined evidence boundary, and its real benefits are impressive
Where to go next What BPC-157 is and what the research shows What the research actually shows about BPC-157 What